

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

AMERIGEN PHARMACEUTICALS LIMITED and  
ARGENTUM PHARMACEUTICALS LLC  
Petitioners,

v.

JANSSEN ONCOLOGY, INC.  
Patent Owner.

---

Case IPR2016-00286<sup>1</sup>  
Patent 8,822,438 B2

---

**DECLARATION OF MATTHEW B. RETTIG, M.D.  
IN SUPPORT OF JANSSEN ONCOLOGY, INC.'S  
PATENT OWNER RESPONSE**

---

<sup>1</sup> Case IPR2016-01317 has been joined with this proceeding.

## TABLE OF CONTENTS

I.	Introduction.....	1
A.	Engagement.....	1
B.	Background and Qualifications.....	1
C.	Compensation and Prior Testimony.....	4
D.	Materials Considered .....	4
II.	Legal Standards Regarding Patentability.....	5
III.	Technical Background .....	7
A.	Control of Prostate Growth and Function by Androgens .....	7
1.	Prostate growth and function .....	7
2.	Androgen Synthesis .....	9
3.	Clinical Disorders Associated with Under-Production or Over-Production of Steroids and Their Treatment .....	15
B.	Prostate Cancer and Its Treatment as of August 2006.....	20
1.	Prevalence, Diagnosis, and Early Stage Treatment .....	20
2.	First Line Hormonal Therapy for Metastatic Prostate Cancer.....	22
3.	Metastatic Castration Resistant Prostate Cancer.....	22
C.	Endpoints for Evaluating Response to Prostate Cancer Treatment .....	26
IV.	The ‘438 Patent and its claims .....	28
V.	Claim Construction.....	32
VI.	Person of Ordinary Skill in the Art.....	32
VII.	The Prior Art Relied On by Petitioners.....	33
A.	Gerber (Exhibit 1004).....	33
B.	The Barrie patent (Exhibit 1005).....	36
C.	O’Donnell (Exhibit 1003).....	36
VIII.	Rebuttal to Dr. Serels’s Opinions Concerning Obviousness .....	38

A.	There Was No Scientific Basis in the Prior Art to Add Prednisone to Abiraterone Acetate for Purposes of Glucocorticoid Replacement .....	38
1.	As of August 2006, a POSA Would Understand that Abiraterone Acetate’s Mechanism of Action and Hormonal Side Effects Were Very Different from Ketoconazole.....	38
2.	As of August 2006, a POSA Would Understand that Abiraterone Acetate Did Not Cause Clinical Symptoms Associated with Adrenal Suppression and Resulted in Normal Cortisol Levels.....	43
a.	O’Donnell teaches that abiraterone acetate did not have any significant effect upon cortisol levels in patients.....	43
b.	A POSA Would Have Concluded from the Prior Art as a Whole that Abiraterone Acetate did not Cause Any Clinical Symptoms Requiring Glucocorticoid Replacement.....	48
3.	As of August 2006, a POSA Would Understand that Gerber’s Use of “Glucocorticoid Replacement” with Ketoconazole Did Not Apply to Abiraterone Acetate .....	50
4.	As of August 2006, a POSA Would Not Have Given Glucocorticoids to Prostate Cancer Patients Unless There Was a Clear Clinical Need Because of Their Known Severe Side Effects and their Potential to Fuel the Cancer	51
B.	There Was No Scientific or Clinical Basis in the Prior Art to Add Prednisone to Abiraterone Acetate to Address Mineralocorticoid Excess .....	56
1.	As of August 2006, a POSA Would Understand that Ketoconazole Did Not Cause Mineralocorticoid Excess Syndrome or Symptoms of Hypertension, Hypokalemia, or Fluid Retention .....	56
2.	As of August 2006, Nothing in the Prior Art Would Have Suggested to a POSA that Abiraterone Acetate Would Cause Mineralocorticoid Excess	60
3.	Even if Mineralocorticoid Excess Was Observed, As of August 2006, a POSA Would Understand that It Could Be Managed Without Glucocorticoid Replacement.....	63
C.	There Was No Scientific or Clinical Basis for Believing that the Combination of Abiraterone Acetate and Prednisone Could Be Successful in Achieving the Inventions Claimed in the ‘438 Patent.....	64
1.	As of August 2006, the Prior Art Did Not Teach that Ketoconazole was “Safe and Effective” for the Treatment of mCRPC.....	64

2.	The Prior Art Did Not Provide a Scientific or Clinical Basis for Believing that Prednisone Would be Effective for Treating Cancer .....	70
IX.	Real World Facts Or “Objective Indicia of Non-Obviousness” Support the Non-Obviousness of the ‘438 Patent Invention .....	71
A.	The Invention Claimed in the ‘438 Patent Resulted in Unexpected Clinical Efficacy .....	71
B.	The Invention Claimed in the ‘438 Patent is Embodied in ZYTIGA® Therapy and Contributes Significantly to the Success of ZYTIGA® .....	77
C.	Long Felt But Unsolved Need .....	80
D.	Skepticism and Failure of Others.....	80
1.	The O’Donnell Studies .....	81
2.	Other Failed Phase III Clinical Trials .....	82

I, Matthew B. Rettig, M.D., hereby declare as follows:

**I. INTRODUCTION**

**A. Engagement**

1. I have been retained by counsel for Patent Owner Janssen Oncology Inc. (“Janssen”) to provide expert and testimony as background for the panel of Administrative Patent Judges of the Patent Trial and Appeal Board of the United States Patent and Trademark Office (“Panel”) as it considers issues relating to the patentability of U.S. Patent No. 8,822,438 (the ’438 Patent) (Ex. 1001) in an *inter partes review* requested by Amerigen Pharmaceuticals Ltd. and Argentum Pharmaceuticals LLC (collectively “Petitioners”) in Case No. IPR2016-00286 and Case No. IPR2016-01317.

**B. Background and Qualifications**

2. I am Medical Director of the Prostate Cancer Program of the Institute of Urologic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles (“UCLA School of Medicine”). I am also Professor in the Department of Medicine and the Department of Urology at the UCLA School of Medicine. I am also Chief of the Division of Hematology-Oncology for the Veteran’s Administration (VA) Greater Los Angeles Healthcare System in West Los Angeles. In addition, I serve as the Director of the Operation Mend Project to Enhance Cancer Care for Veterans, a collaboration between UCLA and the VA Greater Los Angeles Healthcare System to enhance cancer care for veterans.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.